Tularemia:: History, epidemiology, pathogen physiology, and clinical manifestations

被引:441
作者
Sjostedt, Anders [1 ]
机构
[1] Umea Univ, Dept Clin Bacteriol, S-90185 Umea, Sweden
来源
FRANCISELLA TULARENSIS: BIOLOGY, PATHOGENICITY, EPIDEMIOLOGY, AND BIODEFENSE | 2007年 / 1105卷
关键词
Francisella; tularemia; epidemiology; pathogen physiology; clinical manifestations;
D O I
10.1196/annals.1409.009
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
Francisella tularensis has been recognized as a human pathogen for almost 100 years and is the etiological agent of the zoonotic disease tularemia. Soon after its discovery, it became recognized as an important pathogen in several parts of the world, for example, in the United States and Soviet Union. The number of tularemia cases in the two countries peaked in the 1940s and has thereafter steadily declined. Despite this decline, there was still much interest in the pathogen in the 1950s and 1960s since it is highly infectious and transmissible by aerosol, rendering it a potent biothreat agent. In fact, it was one of the agents that was given the highest priority in the offensive programs of the United States and Soviet Union. After termination of the offensive programs in the 1960s, the interest in E tularensis diminished significantly and little research was carried out for several decades. Outbreaks of tularemia during the last decade in Europe, for example, in Kosovo, Spain, and Scandinavia, led to a renewed public interest in the disease. This, together with a massive increase in the research funding, in particular in the United States since 2001, has resulted in a significant increase in the number of active Francisella researchers. This article summarizes, predominantly with a historical perspective, the epidemiology and clinical manifestations of tularemia and the physiology of E tularensis.
引用
收藏
页码:1 / 29
页数:29
相关论文
共 113 条
[11]  
Centers for Disease Control and Prevention (CDC), 2002, MMWR Morb Mortal Wkly Rep, V51, P181
[12]   Changes of the epidemiology and the clinical picture of tularemia in Southern Moravia (the Czech Republic) during the period 1936-1999 [J].
Cerny, Z .
EUROPEAN JOURNAL OF EPIDEMIOLOGY, 2001, 17 (07) :637-642
[13]   Autophagy-mediated reentry of Francisella tularensis into the endocytic compartment after cytoplasmic replication [J].
Checroun, Claire ;
Wehrly, Tara D. ;
Fischer, Elizabeth R. ;
Hayes, Stanley F. ;
Celli, Jean .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2006, 103 (39) :14578-14583
[14]   Characterization of two unusual clinically significant Francisella strains [J].
Clarridge, JE ;
Raich, TJ ;
Sjosted, A ;
Sandstrom, G ;
Darouiche, RO ;
Shawar, RM ;
Georghiou, PR ;
Osting, C ;
Vo, L .
JOURNAL OF CLINICAL MICROBIOLOGY, 1996, 34 (08) :1995-2000
[15]   Virulent and avirulent strains of Francisella tularensis prevent acidification and maturation of their phagosomes and escape into the cytoplasm in human macrophages [J].
Clemens, DL ;
Lee, BY ;
Horwitz, MA .
INFECTION AND IMMUNITY, 2004, 72 (06) :3204-3217
[16]  
Conlan J Wayne, 2004, Expert Rev Vaccines, V3, P307
[18]   Mice vaccinated with the O-antigen of Francisella tularensis LVS lipopolysaccharide conjugated to bovine serum albumin develop varying degrees of protective immunity against systemic or aerosol challenge with virulent type A and type B strains of the pathogen [J].
Conlan, JW ;
Shen, H ;
Webb, A ;
Perry, MB .
VACCINE, 2002, 20 (29-30) :3465-3471
[19]  
DAHLSTRAND S, 1971, Scandinavian Journal of Infectious Diseases, V3, P7
[20]   Tularemia as a biological weapon - Medical and public health management [J].
Dennis, DT ;
Inglesby, TV ;
Henderson, DA ;
Bartlett, JG ;
Ascher, MS ;
Eitzen, E ;
Fine, AD ;
Friedlander, AM ;
Hauer, J ;
Layton, M ;
Lillibridge, SR ;
McDade, JE ;
Osterholm, MT ;
O'Toole, T ;
Parker, G ;
Perl, TM ;
Russell, PK ;
Tonat, K .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2001, 285 (21) :2763-2773